These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28641031)

  • 61. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
    Musso G; Gambino R; Cassader M; Pagano G
    Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.
    Do A; Ilagan-Ying YC; Mehal WZ; Lim JK
    Expert Opin Drug Discov; 2021 Feb; 16(2):125-134. PubMed ID: 33086894
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel therapeutic targets for nonalcoholic fatty liver disease.
    Eguchi A; Povero D; Alkhouri N; Feldstein AE
    Expert Opin Ther Targets; 2013 Jul; 17(7):773-9. PubMed ID: 23600493
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
    Wree A; Mehal WZ; Feldstein AE
    Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G; Ni Y; Nagata N; Xu L; Ota T
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.
    Hannah WN; Harrison SA
    Clin Liver Dis; 2016 May; 20(2):339-50. PubMed ID: 27063273
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Clanton J; Subichin M
    Surg Clin North Am; 2016 Aug; 96(4):703-15. PubMed ID: 27473796
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current investigational drugs in psoriasis.
    Ryan C; Abramson A; Patel M; Menter A
    Expert Opin Investig Drugs; 2012 Apr; 21(4):473-87. PubMed ID: 22400979
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?
    Handa P; Vemulakonda A; Kowdley KV; Uribe M; Méndez-Sánchez N
    World J Gastroenterol; 2016 Aug; 22(31):6965-71. PubMed ID: 27610009
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH).
    Roberts SK; Majeed A
    Expert Opin Ther Targets; 2021 Oct; 25(10):889-895. PubMed ID: 34727818
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
    [No Abstract]   [Full Text] [Related]  

  • 77. Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
    Devasthale P; Cheng D
    J Med Chem; 2018 Nov; 61(22):9879-9888. PubMed ID: 29986142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nonalcoholic steatohepatitis (NASH) drugs market.
    Cassidy S; Syed BA
    Nat Rev Drug Discov; 2016 Nov; 15(11):745-746. PubMed ID: 27807356
    [No Abstract]   [Full Text] [Related]  

  • 79. Liver disease: Conscious uncoupling in NASH.
    Villanueva MT
    Nat Rev Drug Discov; 2017 Mar; 16(4):238-239. PubMed ID: 28356593
    [No Abstract]   [Full Text] [Related]  

  • 80. A perspective on RNA interference-based therapeutics for metabolic liver diseases.
    Alkhouri N; Gawrieh S
    Expert Opin Investig Drugs; 2021 Mar; 30(3):237-244. PubMed ID: 33470860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.